TrialAnnals of hematology2020

Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia.

Tim H Brümmendorf et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.